ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO669

PBI-4050 Prevents Diabetic Nephropathy and Protects β-Cells in NOD Mice: A Model of Type 1 Diabetes

Session Information

Category: Diabetes

  • 501 Diabetes Mellitus and Obesity: Basic - Experimental

Authors

  • Gagnon, Lyne, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Hince, Kathy, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Sarra-Bournet, François, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Tremblay, Mikaël, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Cloutier, Marie-Pier, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Létourneau, Sylvie, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Laurin, Pierre, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Grouix, Brigitte, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Leblond, Francois A., Prometic BioSciences Inc., Laval, Quebec, Canada
Background

PBI-4050, a novel first-in-class orally active antifibrotic compound, which is currently in a phase II clinical trial, significantly reduced glycated hemoglobin (HbA1c) after 12 and 24 weeks of treatment in patients with type 2 diabetes and metabolic syndrome with elevated HbA1c despite anti-hyperglycemic treatment. PBI-4050 also reduced biomarkers associated to kidney injury. In the present study, we examined whether PBI-4050 may prevent diabetic nephropathy in NOD mice, a model of type 1 diabetes.

Methods

NOD/ShiLtJ female mice (8 weeks of age) received vehicle (water) or PBI-4050 (200 mg/kg/day) by daily gastric gavage for 23 weeks.

Results

In kidney, PBI-4050 protects against lesions by reducing glomerular volume and mesangial cross sectional area. Furthermore, tubular lesions were absent in PBI-4050-treated mice. Tubular dystrophy as PAS granular accumulation was constantly present in proximal tubules of NOD control mice and was completely abrogated by treatment with PBI-4050. Mice treated with PBI-4050 did not develop diabetes. OGTT was also normalized in PBI-4050 treated mice. Despite a reduced number of islets compared to non-diabetic mice, NOD mice treated with PBI-4050 maintained normoglycemia and showed a 30% reduction in the number of islets with grade 4 lesions.

Conclusion

This data suggests that PBI-4050 prevents diabetic nephropathy and complete destruction of β-cells and islets in type 1 diabetes model.

Funding

  • Commercial Support – Prometic Life Sciences Inc.